{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:23:09Z","timestamp":1769826189992,"version":"3.49.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>As new vaccine technologies and platforms, such as nanoparticles and novel adjuvants, are developed to aid in the establishment of a universal influenza vaccine, studying traditional influenza split\/subunit vaccines should not be overlooked. Commercially available vaccines are typically studied in terms of influenza A H1 and H3 viruses but influenza B viruses need to be examined as well. Thus, there is a need to both understand the limitations of split\/subunit vaccines and develop strategies to overcome those limitations, particularly their ability to elicit cross-reactive antibodies to the co-circulating Victoria (B-V) and Yamagata (B-Y) lineages of human influenza B viruses. In this study, we compared three commercial influenza hemagglutinin (HA) split\/subunit vaccines, one quadrivalent (H1, H3, B-V, B-Y HAs) and two trivalent (H1, H3, B-V HAs), to characterize potential differences in their antibody responses and protection against a B-Y challenge. We found that the trivalent adjuvanted vaccine Fluad, formulated without B-Y HA, was able to produce antibodies to B-Y (cross-lineage) on a similar level to those elicited from a quadrivalent vaccine (Flucelvax) containing both B-V and B-Y HAs. Interestingly, Fluad protected mice from a lethal cross-lineage B-Y viral challenge, while another trivalent vaccine, Fluzone HD, failed to elicit antibodies or full protection following challenge. Fluad immunization also diminished viral burden in the lungs compared to Fluzone and saline groups. The success of a trivalent vaccine to provide protection from a cross-lineage influenza B challenge, similar to a quadrivalent vaccine, suggests that further analysis of different split\/subunit vaccine formulations could identify mechanisms for vaccines to target antigenically different viruses. Understanding how to increase the breadth of the immune response following immunization will be needed for universal influenza vaccine development.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1002286","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T05:06:57Z","timestamp":1664514417000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus"],"prefix":"10.3389","volume":"13","author":[{"given":"Mallory L.","family":"Myers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De\u2019Marcus D.","family":"Woolfork","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regan K.","family":"Stradtmann-Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Maldonado-Puga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin W.","family":"Bock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyhan","family":"Boyoglu-Barnum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubza","family":"Syeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Creanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derron A.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Kanekiyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audray K.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1093\/infdis\/jiy728","article-title":"Making universal influenza vaccines: Lessons from the 1918 pandemic","volume":"219","author":"Morens","year":"2019","journal-title":"J Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1906.121478","article-title":"Pandemic influenza planning, united states, 1978-2008","volume":"19","author":"Iskander","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1916585116","article-title":"Divergent evolutionary trajectories of influenza b viruses underlie their contemporaneous epidemic activity","volume":"117","author":"Virk","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2013.824709","article-title":"The evolving history of influenza viruses and influenza vaccines","volume":"12","author":"Hannoun","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis574","article-title":"Effectiveness of seasonal influenza vaccines in the united states during a season with circulation of all three vaccine strains","volume":"55","author":"Treanor","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1017\/S0022172400022610","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and b viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J Hyg (Lond)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22908","article-title":"Correlates of protection to influenza virus, where do we go from here","volume":"9","author":"Cox","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1126\/science.aaq0620","article-title":"Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin","volume":"362","author":"Laursen","year":"2018","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02477-07","article-title":"Crystal structure of unliganded influenza b virus hemagglutinin","volume":"82","author":"Wang","year":"2008","journal-title":"J Virol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03365-x","article-title":"Quadrivalent influenza nanoparticle vaccines induce broad protection","volume":"592","author":"Boyoglu-Barnum","year":"2021","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00286-17","article-title":"Chimeric hemagglutinin constructs induce broad protection against influenza b virus challenge in the mouse model","volume":"91","author":"Ermler","year":"2017","journal-title":"J Virol"},{"key":"B13","article-title":"Early estimates of seasonal influenza vaccine effectiveness - united states, January 2015","volume":"64","author":"Flannery","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4161\/hv.8.1.17623","article-title":"The rationale for quadrivalent influenza vaccines","volume":"8","author":"Ambrose","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"B15","article-title":"Prevention. influenza activity\u2013united states and worldwide, 2007-08 season","volume":"57","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu664","article-title":"Impact of influenza b lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012","volume":"59","author":"Heikkinen","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01176-z","article-title":"Cell-based quadrivalent inactivated influenza virus vaccine (Flucelvax((R)) Tetra\/Flucelvax Quadrivalent((R))): A review in the prevention of influenza","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166107","article-title":"Estimating the lineage dynamics of human influenza b viruses","volume":"11","author":"Nyirenda","year":"2016","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0042-6822(90)90186-U","article-title":"Cocirculation of two distinct evolutionary lineages of influenza type b virus since 1983","volume":"175","author":"Rota","year":"1990","journal-title":"Virology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1900008","DOI":"10.1183\/13993003.00008-2019","article-title":"Tropism of influenza b viruses in human respiratory tract explants and airway organoids","volume":"54","author":"Bui","year":"2019","journal-title":"Eur Respir J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.27.3.524-528.1989","article-title":"Improved colorimetric assay for detecting influenza b virus neutralizing antibody responses to vaccination and infection","volume":"27","author":"Tannock","year":"1989","journal-title":"J Clin Microbiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1901325","DOI":"10.1183\/13993003.01325-2019","article-title":"When \u201cB\u201d becomes \u201cA\u201d: the emerging threat of influenza b virus","volume":"54","author":"Sharma","year":"2019","journal-title":"Eur Respir J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e20154643","DOI":"10.1542\/peds.2015-4643","article-title":"Hospitalization for influenza a versus b","volume":"138","author":"Tran","year":"2016","journal-title":"Pediatrics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.13.1435","article-title":"Emergence of influenza b viruses with reduced sensitivity to neuraminidase inhibitors","volume":"297","author":"Hatakeyama","year":"2007","journal-title":"JAMA."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.08.023","article-title":"Neuraminidase inhibitors for influenza b virus infection: efficacy and resistance","volume":"100","author":"Burnham","year":"2013","journal-title":"Antiviral Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1222908","article-title":"Highly conserved protective epitopes on influenza b viruses","volume":"337","author":"Dreyfus","year":"2012","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41467-018-07970-9","article-title":"Cross-lineage protection by human antibodies binding the influenza b hemagglutinin","volume":"10","author":"Liu","year":"2019","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1805268115","article-title":"Biological sex affects vaccine efficacy and protection against influenza in mice","volume":"115","author":"Fink","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1189\/jlb.0811427","article-title":"Mechanisms of sex disparities in influenza pathogenesis","volume":"92","author":"Klein","year":"2012","journal-title":"J Leukoc Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1830685","article-title":"The effect of sex on responses to influenza vaccines","volume":"17","author":"Denly","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","article-title":"A statistically defined endpoint titer determination method for immunoassays","volume":"221","author":"Frey","year":"1998","journal-title":"J Immunol Methods"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/s41467-021-21954-2","article-title":"A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies","volume":"12","author":"Creanga","year":"2021","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01433-09","article-title":"Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies","volume":"84","author":"Martinez-Sobrido","year":"2010","journal-title":"J Virol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00662-12","article-title":"The influenza a virus PB2, PA, NP, and M segments play a pivotal role during genome packaging","volume":"86","author":"Gao","year":"2012","journal-title":"J Virol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.1187816","article-title":"Permissive secondary mutations enable the evolution of influenza oseltamivir resistance","volume":"328","author":"Bloom","year":"2010","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-0211-9_16","article-title":"Histopathologic evaluation and scoring of viral lung infection","volume":"2099","author":"Meyerholz","year":"2020","journal-title":"Methods Mol Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240563","article-title":"Development of a histopathology scoring system for the pulmonary complications of organophosphorus insecticide poisoning in a pig model","volume":"15","author":"Hulse","year":"2020","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkh340","article-title":"MUSCLE: multiple sequence alignment with high accuracy and high throughput","volume":"32","author":"Edgar","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.20084","article-title":"UCSF chimera\u2013a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J Comput Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and efficacy of MF59-adjuvanted vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.08.064","article-title":"An influenza b outbreak during the 2007\/2008 winter among appropriately immunized elderly people living in a nursing home","volume":"28","author":"Camilloni","year":"2010","journal-title":"Vaccine"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.078","article-title":"Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against b viruses of the B\/Victoria or B\/Yamagata lineages","volume":"27","author":"Camilloni","year":"2009","journal-title":"Vaccine."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy103","article-title":"A universal influenza vaccine: The strategic plan for the national institute of allergy and infectious diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0243-3","article-title":"Novel vaccine technologies for the 21st century","volume":"20","author":"Mascola","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc\u03b3R interactions for protection against influenza virus in vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.32607\/20758251-2019-11-4-22-32","article-title":"Non-neutralizing antibodies directed at conservative influenza antigens","volume":"11","author":"Sedova","year":"2019","journal-title":"Acta Naturae"},{"key":"B49","doi-asserted-by":"publisher","first-page":"103131","DOI":"10.1016\/j.isci.2021.103131","article-title":"Synergistic effect of non-neutralizing antibodies and interferon-\u03b3 for cross-protection against influenza","volume":"24","author":"Shibuya","year":"2021","journal-title":"iScience"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0056-x","article-title":"Next-generation influenza vaccines: opportunities and challenges","volume":"19","author":"Wei","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.03.024","article-title":"Vaccine options for influenza: thinking small","volume":"53","author":"Schepens","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1107","article-title":"Assessment of enhanced influenza vaccination finds that FluAd conveys an advantage in mice and older adults","volume":"9","author":"Kavian","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003150","article-title":"Human monoclonal antibodies broadly neutralizing against influenza b virus","volume":"9","author":"Yasugi","year":"2013","journal-title":"PLoS Pathog"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00107","article-title":"The future of flu: A review of the human challenge model and systems biology for advancement of influenza vaccinology","volume":"9","author":"Sherman","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12985-019-1171-3","article-title":"The tree shrew is a promising model for the study of influenza b virus infection","volume":"16","author":"Yuan","year":"2019","journal-title":"Virol J"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1135(00)00171-1","article-title":"Cytokines in the pathogenesis of influenza","volume":"74","author":"Van Reeth","year":"2000","journal-title":"Vet Microbiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/sj.icb.7100026","article-title":"A question of self-preservation: immunopathology in influenza virus infection","volume":"85","author":"La Gruta","year":"2007","journal-title":"Immunol Cell Biol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3390\/v14061299","article-title":"Expanding mouse-adapted yamagata-like influenza b viruses in eggs enhances In vivo lethality in BALB\/c mice","volume":"14","author":"Pekarek","year":"2022","journal-title":"Viruses"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010331","article-title":"Oil-in-water emulsion adjuvant with influenza vaccine in young children","volume":"365","author":"Vesikari","year":"2011","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12985-015-0435-9","article-title":"Matrix-m adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine","volume":"12","author":"Cox","year":"2015","journal-title":"Virol J"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1415684","article-title":"Adjuvanted influenza vaccines","volume":"14","author":"Tregoning","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59 - an innately attractive adjuvant formulation","volume":"30","author":"O\u2019Hagan","year":"2012","journal-title":"Vaccine."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.746447","article-title":"Mosaic hemagglutinin-based whole inactivated virus vaccines induce broad protection against influenza b virus challenge in mice","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2023.1283355","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1002286\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T06:40:55Z","timestamp":1694587255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1002286\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2022.1002286"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1002286","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fimmu.2023.1283355","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"article-number":"1002286"}}